Observational studyNeurocritical care2026
Impact of FXIII Levels on Hematoma Expansion and Outcomes in Patients with Spontaneous Intracranial Hemorrhage: A Prospective Observational Cohort Study of 132 Patients.
Observational study in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiminished levels of FXIII are significantly correlated with hematoma expansion (HE) and unfavorable clinical outcomes. Although the crucial function of FXIII in coagulation is well-recognized, the connection between FXIII deficiency and either HE or negative prognosis in patients with spontaneous intracerebral hemorrhage (sICH) is not well understood.
methodsPatients with sICH were confirmed through baseline computed tomography scans conducted within 6 h of symptom onset. Plasma FXIII levels were assessed at the time of admission using a standardized enzyme-linked immunosorbent assay. Restricted cubic spline models were employed to explore potential nonlinear relationships between admission FXIII levels and both hematoma expansion and clinical outcomes. Multivariable logistic regression analyses were performed to ascertain the association between FXIII levels and functional outcomes at 3 months postonset.
resultsIn the study cohort of 132 patients with sICH, 49 experienced HE. The median admission level of FXIII was significantly lower in patients with HE, with a median [IQR] of 8.21 mg/L (6.33, 10.37), compared with those without HE, who had a median value [IQR] of 11.68 mg/L (8.49, 21.20), p < 0.001. A deficiency in Factor XIII, defined as a plasma level < 10 mg/L, was associated with HE, with a fivefold increase in risk as indicated by an adjusted odds ratio of 5 (95% CI 2.031-12.325; p < 0.001). Furthermore, multivariable analysis revealed that this deficiency was associated with poor functional outcomes, defined as a modified Rankin Scale (mRS) score of > 3, by a factor of 59.45 (OR 59.45, 95% CI 7.258-487.006; p < 0.001), and increased the risk of mortality by a factor of 12.07 (OR 12.07, 95% CI 2.526-57.669; p = 0.002) in patients with sICH.
conclusionsIn a prospective observational cohort study of patients with sICH, FXIII deficiency was found to be associated with HE and poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.